Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients.

ABSTRACT:

Introduction

Fibromyalgia (FM) is a chronic disorder characterized by widespread pain with an enormous symptom burden. Its treatment efficacy is limited. Its pathogenesis involves immune dysregulation, which includes interleukin-6 (IL-6) production.

Methods

We herein reported a case series of FM patients receiving subcutaneous tocilizumab at our institution. FM symptoms were evaluated by the revised Fibromyalgia Impact Questionnaire (FIQR), which included pain level, and the fibromyalgianess scale based on the 2016 criteria of the American College of Rheumatology (ACR). FM symptoms were compared using the Wilcoxon signed-rank test. Neutrophils from primary FM patients and matched healthy controls were also isolated for transcriptome analysis.

Results

We presented a to

SUBMITTER: Tang KT 

PROVIDER: S-EPMC10376766 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature